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Atherosclerosis and its thrombotic complications are responsible for remarkably high numbers of deaths. The combination of in
vitro,exvivo,andin vivo experimental approaches haslargely contributed to a better understanding of the mechanismsunderlying
the atherothrombotic process. Indeed, diﬀerent animalmodels have been implemented in atherosclerosisand thrombosisresearch
in order to provide new insights into the mechanisms that have already been outlined in isolated cells and protein studies.
Yet, although no model completely mimics the human pathology, large animal models have demonstrated better suitability
for translation to humans. Indeed, direct translation from mice to humans should be taken with caution because of the well-
reported species-related diﬀerences. This paper provides an overview of the available atherothrombotic-like animal models, with
a particular focus on large animal models of thrombosis and atherosclerosis, and examines their applicability for translational
research purposes as well as highlights species-related diﬀerences with humans.
1.Animal ModelsasaTool for
PreclinicalTranslation
Atherosclerotic plaques may appear early in life and their
advance into severe, symptomatic plaques, depends on
the coexistence of risk factors. Rupture or damage of
lipid- rich coronary plaques triggers subsequent thrombosis
(i.e., atherothrombotic event), and this is possibly the
most important mechanism leading to the onset of acute
coronary syndromes (ACSs) and ischemic sudden death.
Atherothrombosis involves a large number of platelet- and
vessel- surface receptors, platelet-related signaling path-
ways, and the activation of the coagulation cascade all of
which interplay to form the mural thrombotic clot [1].
In vitro studies have provided relevant information about
mechanistic questions and have aided in the development
of potent and selective antithrombotic drugs. Yet, in vivo
approaches are necessary to address the hypothesis aimed
at the prevention/treatment of human disease. Furthermore,
in vitro research cannot mimic the hemodynamic and
hemorrheology conditions that occur during the generation
and propagation of thrombi in vivo, nor the vascular wall
lesion resembling an atherosclerotic plaque. The availabil-
ity of genetically modiﬁed mouse strains has enabled to
elucidate new pathways involved in the development of
cardiovascular disease [2]. However, although their useful-
ness in uncovering speciﬁc gene functions is overwhelming,
their utility to extrapolate the ﬁndings to human disease
or as preclinical models to prove validity pharmacologic
agents is less appealing. Furthermore, it has been questioned
whether these models should be trusted blindly, since com-
pensating mechanisms and redundancies may aﬀect their
atherothrombotic phenotype. In contrast, the development
and implementation of animal models of atherosclerosis and
thrombosis, besides providing valuable information about
the mechanisms involved in thrombus formations, have
become valuable tools for the discovery of a number of com-
pounds that, in fact, are now successfully being used for the2 Journal of Biomedicine and Biotechnology
treatment and prevention of the atherothrombotic diseases
[3].
Rats, rabbits, dogs, pigs, and monkeys are well-estab-
lished animal models of atherosclerosis and thrombo-
sis whereas hamster, mouse, cat, and guinea pig have also
been used, although to a lesser extent [14]. Overall, pigs and
monkeys have been better suited to study atherosclerosis
and arterial thrombosis than rats, rabbits and dogs. An
ideal animal model should be representative of the human
atherothrombotic disease but, unfortunately, the majority
of assays are performed in healthy animals not addressing
the underlying atherosclerotic cause. In addition, not all
the large experimental animal models have human resem-
blance and validity and species-related diﬀerences should
be regarded before interpreting the data. Table 1 highlights
the major similarities and diﬀerences between humans and
nonhuman primates, swine, and dogs in the thrombotic
system.
2.Small versusLargeAnimal Models
Small animals, primarily rodents and rabbits, havebeen used
extensively for atherosclerosis and thrombosis research [15].
Some of the reasons for the frequent use of small animal
models in research include, low cost, ready availability,
reduced ethical concern compared to large animals (espe-
cially nonhuman primates), and small size that limits the
quantitiesofnewagentsrequired for in vivo screening. These
characteristicshavepermittedrapidevaluationofnewagents
in suﬃciently large number of animals to perform mean-
ingful statistical analyses. However, mice do not develop
atherosclerosis without genetic manipulation since they have
a lipid physiology that is radically diﬀerent from that in
humans, most of the cholesterol being transported in HDL-
likeparticles. Yet, their easy and practicalhandling, has made
advantageous the use of murine models of vascular injury
to study thrombosis [16]. In this regard, special attention
should be given to the intravital microscopy usefulness in
the mice model of thrombosis since it allows testing the
in vivo relevance of the in vitro observations. Indeed, the
study of microvascular thrombosis by intravital microscopy
(e.g., mesenteric arteries) represents a particularly useful
tool for characterization of speciﬁc cells types involved in
the developing thrombus as well as evaluating the eﬀect
of diﬀerent inﬂammatory pathological conditions, such as
obesity, in vascular reactivity [17]. In addition, the dynamics
of thrombus formation can be studied with very high
resolution in these thin, transparent vessels thus providing a
great insight into speciﬁc cellular and molecular interactions
within thedevelopingthrombus[18].Inaddition,therodent
models oﬀer numerous immunological approaches (e.g.,
monoclonal antibodies). Speciﬁcally, mice models provide
genetically modiﬁed animal strains with deﬁned defects in
platelet function that open new ways to identify the individ-
ual roles and the interplay of platelet proteins in thrombus
formation [19, 20]. However, rodent microvascular models
of thrombosis need to be complemented by macrovascular
models of thrombosis in which vessel characteristics are
more similar to human coronary, carotid, and cerebral arter-
ies. As a result, large animal models may provide a more rel-
evant representation of the type of thrombus formation that
leads to clinical cardiovascular disease complications such as
AMI and stroke. One example in which diﬀerent results have
been obtained between microvascular and macrovascular
thrombosis models involved analysis of relevant tissue factor
(TF) pools. Studies in groups using the same low-TF
expressing mice reached diﬀerent conclusions regarding the
relevant source of TF in vascular thrombus formation, one
group supporting the contribution of vessel-related TF [21],
whereas the other emphasizes the key role of blood-borne
TF as a major thrombogenic stimuli [22]. We and others,
by using large animal models of thrombosis, have supported
the hypothesis that vessel wall-derived TF is a primary con-
tributor to arterial thrombus formation and propagation,
yet, blood-borne TF may also contribute depending on the
triggering lesion and the shear rate [23, 24].
Besidesallthis,anaccuratein-depthdeterminationofthe
mouse haemostatic system (i.e., coagulation and ﬁbrinolytic
systems, platelet structure, and platelet receptor/enzyme
system) is still lacking, as nicely reviewed by Tsakiris et al,
[25]a n dW a r e[ 26], and species-related diﬀerences between
rodents and humans should also be considered before
interpreting the data. For instance, platelet counts in mice
on average are four times those of humans and platelets are
only approximately one half the volume of human platelets.
All these reasons may help to explain why rodents have not
been as widely used as larger animal models (e.g., swine) to
test possible therapeutic usefulness of antithrombotic agents
[27]. In fact, more advanced experimental models including
nonhuman primates, pigs, and dogs are usually reserved to
test the antithrombotic eﬃcacy/safety of new compounds
before clinical testing. Indeed, large animal models present
disadvantages which are primarily the reverse of the advan-
tages of small animal models (high cost, heightened ethical
concerns, less precise genetic characterization, diﬃculties
involved in maintaining the colonies and their handling and
a scarcity of transgenic models, and antibodies); however,
their human-resemblance makes them an attractive tool to
provide new insights into the atherothrombotic ﬁeld.
Because of similarities between human and nonhu-
man primates [28], nonhuman primate animal models are
believed to be better suited to investigate human cardiovas-
cular pathology (atherosclerosis, thrombus formation and
dissolution, and therapeutic interventions). In 1965 Malinov
and Maruﬀo[ 29] published studies performed using the
monkey as animal model to evaluate aortic atherosclero-
sis. More recently, familial LDL receptor deﬁciency with
atherosclerosis has been reported in rhesus monkey [30,
31]. Nonhuman primate thrombosis models, mainly arte-
riovenous shunt models are good models to evaluate novel
thrombotic agents prior to administration of the drugs to
human in clinical trials [32]. In fact, nonhuman primates
platelet function, coagulation, and ﬁbrinolytic system and
drug pharmacokinetics resemble those in humans [28], and
some immunologic overlap allows utilization of available
assays. However, nowadays, the use of primates is con-
strained by obvious species speciﬁc (risk of extinction) andJournal of Biomedicine and Biotechnology 3
Table 1: Diﬀerences between large animal models and humans in the thrombotic system and other parameters that may inﬂuence anti-
thrombotic eﬀectiveness.
Specie Diﬀerences with humans Human similarities Reference
Nonhuman primates
Platelet function, coagulation,ﬁbrinolysis
and therapeutic interventions
(arteriovenous vascular graft or surgical
endarterectomy)
Harker et al. [4]
Diﬀerent digestive metabolic pathways Johnson et al. [5]
Swine
Von Willebrand levels close to humans Denis and Wagner [6]
Physiological hematologicvalues Gross [7]
Accelerated intrinsic cascade activity
because of higher levels of coagulation
factors (IX, XI, XII)
Olsen et al. [8]
Iron deﬁciency that may aﬀect
erythrocytic volumes Pedersen et al. [9]
GPIIb/IIIa protein Royo et al. [10]
Aortic EC do not contain mature vWF Royo and Badimon [11]
Dogs
Vascular and platelet responsiveness to
thromboxane and endoperoxide
analogues close to humans
Burke et al. [12]
Platelets appear to play a greater role in
thrombus formation than in humans Strony et al. [13]
EC: endothelial cells; VWF: Von Willebrand factor.
ﬁnancial concerns, as well as the complexity, training and
expertise required to perform this animal approach. This
has supported the use of a more accessible and less costly
large animal models, such as the porcine model, which fairly
reproduces human atherosclerotic and thrombotic disease as
detailed below.
3. The Pig as a Tool for Atherothrombotic
Disease
Thepigisaverygoodmodelbecauseitdevelopsspontaneous
atherosclerotic lesions, has a human-like cardiovascular
anatomy, and even may develop sudden death when under
stress (WhiteBelgian breed)[33–37]. Inaddition, swine oﬀer
the ability to evaluate their coronary arteries rather than
larger central vessels (mostly studied in smaller animals).
The heart of the pig is anatomically similar to humans
except for the presence of the left azygous (hemiazygous)
vein, which drains the intercostal system into the coronary
sinus [38], and for the size, which tends to be a bit
smaller. Regarding the heart, blood supply is mostly right
side dominant since it originates from the posterior septal
artery [37] and both anatomy and function of the pig cor-
onary system as well as the histological anatomy of the
aorta are comparable to humans. However, on the other
hand, pig blood vessels are more friable and prone to
vasospasm during manipulation, and thus require careful
handling during blood withdrawals [39]. In relation to
pig hemodynamics, either physiological cardiac function
or mechanically induced myocardial infarction and the
subsequent arrhythmogenic activity in reperfusion is also
analogous to humans as well as the wound healing process
[40].
Pig atherosclerosis, diverging to small animal models,
is generally quite slow and occurs both spontaneously (i.e.,
intake regular chow) and by experimental induction (i.e.,
intake of a high atherogenic diet) [41–43]. Moreover, if
allowed to develop over time, mild atherosclerotic lesions
ﬁrst appear in coronary arteries and both atherosclerotic
plaque distribution and composition (lipid, ﬁbrinogen,
smooth muscle cells, and macrophage content) [43] follows
a pattern comparable to that of humans [44–46]. Human-
likepiglipoproteinmetabolisms may helpto explain,in part,
the above mentioned similarities [47]. Finally, unlike other
animal models, after gradual occlusion of the coronary
vessels induced by both balloon injury and atherogenic diet,
swine may develop the coronary restenosis syndrome as
humans [40, 44, 45, 48, 49].
Overall, literature reports three types of swine “athe-
rothrombotic-like” approaches that may, sometimes, be com-
bined including feeding animals with fat-rich diets, extra-
corporeal arteriovenous shunts, and intravascular damage
interventions (balloon, grafting, etc).
3.1.Diet-Induced Atherosclerosis. Asmentioned above,swine
candevelophypercholesterolemia andatheroscleroticlesions
by diet induction (high-cholesterol content diets), reaching
plasma cholesterol levels similar to those in human. After
a 50-day period with a standard hypercholesterolemic diet
we have previously observed that almost all pigs developed
early atherosclerotic lesions (fatty streaks) localized in the
abdominal aorta and to a lesser extent in the coronary
arteries [43]. In such cases, lesion composition was similar
to early-stage human atherosclerosis [43]. As expected,
increasing the diet induction period to 100 and 150 days
was associated with a higher degree of lesion severity made4 Journal of Biomedicine and Biotechnology
evidentwhensuitablefatstainwasapplied.Notwithstanding,
animals employed in these long-period studies tend to be
within the prepuberty period, and in consequence their
lesions are not as severe as those developed in adult humans
over the years. Older animals (over 6 months) can be
used to obtain atherosclerotic models of higher human re-
semblance [50], but management becomes more diﬃcult
because of their considerable weight (up to 150kg). To
overcome size-related problems, the minipigs are becoming
increasingly used. Indeed, miniature swine are preferable to
commercial swine as animal models because of their small
size and small growth rate that allows them to maintain
weight and size throughout adulthood. They are docile
and easily handled and there are several miniature strains
disposable to better ﬁt scientiﬁc purposes. Miniature pigs
havebeenusedinseveralﬁeldsofbiomedicalresearchstudies
such as cardiovascular disease (models of thrombosis and
restenosis), obesity, diabetes, and transplantation, however,
the principal disadvantage for using miniature pigs as a
substituteofcommonpigsarethemaintenancerequirements
andthehighcostoftheanimals.Asaconsequence,miniature
pigs’ breeders are not largely distributed in all countries.
3.2.Extracorporeal ArteriovenousShunts. Theex vivoporcine
model of thrombus formation (e.g., ﬂow chambers coupled
to extracorporeal shunts) has become essential for testing
the eﬀect of blood elements and rheology as well as
atherosclerotic vessel components in thrombus formation in
a controlled manner [1, 51–59]. Indeed, it has allowed to
evaluate the thrombogenic eﬀect of diﬀerent atherosclerotic
plaque constituents (e.g., collagen, fatty streaks, smooth
musclecells, etc)[51–53], diﬀerentdegreesofshear stress (to
mimic diﬀerent degrees of stenosis) [54, 55], and to evaluate
the antiplatelet eﬀects of new antithrombotic compounds
[43, 53, 55, 58, 60]. Furthermore, these ex vivo models of
thrombosis oﬀer the opportunity to evaluate, in an easy and
reproducible manner, the interaction of a given compound
with the blood and vascular compartment and consider any
metabolic transformation.
Baumgartner developed the ﬁrst popular annular per-
fusion chamber that helped to advance the knowledge and
understanding of platelet adhesion to the subendothelium
under laminar ﬂow [61]. Since then, other ex vivo chamber
systems have been developed for investigating prosthetic
and biologics substrates surfaces over a broad range of ﬂow
conditions [62, 63]. In fact, although atherosclerosis pref-
erentially occurs in areas of turbulent blood ﬂow and low
ﬂuid shear stress, thrombosis is induced by high shear stress.
Moreover, in atherosclerotic vessels, laminar ﬂow conditions
maynotbemaintainedsincestenoticnarrowing inducesﬂow
disturbances that modify cell-cell and cell-vessel interactions
as well as the local concentration of ﬂuid-phase chemical
mediators necessary for cell interaction. In this regard, we
have developed an extracorporeal perfusion system (the
Badimonchamber) [64]thatallowstoinvestigatethedynam-
ics of plateletdeposition and thrombus formation (a)on dif-
ferent surfaces (biological and prosthetic materials) [65, 66];
(b) under a broad range of patho-physiological ﬂow con-
ditions including laminar and nonparallel streamline ﬂows
[54, 67, 68]; (c) with varying perfusing blood treatments.
This chamber has helped to improve the understanding
of the pathophysiology of the acute coronary syndromes
[52, 64], to characterize the thrombogenicity of diﬀerent
degrees of vascular injury [52]a n dd i ﬀerent atheromatous
components[51],evaluatethethrombogenicityassociatedto
several synthetic/prosthetic surfaces [65, 66]a n d / o rs e v e r a l
plasma components(cholesterol,glucoselevels,etc.)[69,70]
and has become a useful tool for the study and screen
of new antithrombotic and platelet-inhibitory compounds
upon exposure of human atherosclerotic and/or stented
vessels [51, 53, 55, 71–75].
3.3. Intravascular Interventions. Coronary artery interven-
tions, such as balloon angioplasty and stenting, have become
established treatments for symptomatic coronary artery
disease [76]. Although stent implantation initially appeared
promising,withratesof20%to30%inso-calledideallesions
[77], there is still a high rate of vessel reclosure resulting in
the need for repeat procedure [78]. Many animal models
have provided insights into the mechanisms of angioplasty
and in-stent restenosis in diﬀerent metabolic disorders
(obesity, diabetes, etc.) and are widely used to examine
candidate drug inhibitors that might be used in clinical eval-
uation. Experience suggests, however, that porcine coronary
stenting is a very suitable model because injury response is
similar to human vessels with an adaptive response being
more profound in animals fed a hypercholesterolemic diet
[79]. Moreover, as stated above, since size and anatomic
distribution of porcine coronary arteries are similar to
those of the human, angiography, intravascular ultrasound,
instrumentation, and stent deployment are all similar to
the clinical situation. On the other hand, a number of
strategies have also been adopted in an eﬀort to reduce
both the acute thrombogenic potential of metallic stents
and the stent-induced neointimal thickening [80]. As such,
oral administration of endothelin receptor antagonists [81]
or tranilast [82], capable of modulating the inﬂammatory
tissue responses, has been demonstrated to be eﬃcacious in
preventing neointima formation after coronary stenting in
swine. Similarly, subcutaneous low-molecular-weight hep-
arin administration on top of acetylsalicylic acid has also
shown to reduce neointimal proliferation after coronary
stent implantation in hypercholesterolemic minipigs [83]. In
contrast, systemic pharmacological approaches in humans
have been largely disappointing, possibly owing to insuf-
ﬁcient local drug concentration. To solve this limitation,
polymer coated stents were developed as a vehicle for
local drug administration. To date, a number of diverse
biological agents have been shown to elute slowly from
polymer coatings and are associated with reduced neointima
formation in pig models [84, 85].
4.Canine ModelsofAtherosclerosisand
Thrombosis
The dog, as described for rats, is not a good model for
atherosclerosis because they do not develop spontaneousJournal of Biomedicine and Biotechnology 5
atherosclerosisevenunderahigh-cholesterol diet[86].How-
ever, induction of experimental atherosclerosis in dogs has
been achieved by administering high-fat/high-cholesterol
diet deﬁcient in essential fatty acids [87].
As to canine models of thrombosis, Folts and colleagues
[88]describedin1976amodelofrepetitivethrombusforma-
tion,assessed bycyclicﬂow reductionsbyanelectromagnetic
ﬂow probe, in stenosed coronary arteries of open-chest anes-
thetized dogs. The Folts model is based on the combination
of severe, concentric stenosis, and focal intimal injury canine
coronaries (circumﬂex and left anterior descending) [3]. Yet,
this model was lately modiﬁed for its use in both femoral
and/or carotid rabbit arteries. The Folts model mainly
inducesplatelet-richthrombusformation.Hence,incontrast
tothethrombiusuallyresponsibleforAMI,doesnotrespond
to thrombolytic agents likely representing a model of
“thrombolytic-resistant” platelet occlusion rather than acute
thrombosis. Nevertheless, this model is an attractive choice
for initial antithrombotic eﬀectiveness in vivo, especially for
assessing prostaglandin-inhibitor compounds, prostacyclin
mimetics, or platelet GPIIb/IIIa-receptor antagonists (e.g.,
abciximab, tiroﬁban, etc.) [89–92]. In fact, the preclinical
data obtained with this animal model has been further
corroborated in clinical trials such as the EPIC (abciximab)
[93] and PRISM (tiroﬁban) investigators trials [94].
Canine thrombosis can also be challenged by advancing
a thrombogenic coil into a coronary artery in closed-chest
animals [95]. The composition (alloy) and size of the coil
determine the time to occlusive thrombus formation con-
ﬁrmed by a ﬁlling defect distal to the coil. This model, in
contrast to the Folts model, induces platelet-poor and ﬁbrin-
rich thrombus and thus enables to test thrombolytic agents
[96]. Important drawbacks, however, are the high incidence
of ventricular ﬁbrillations (which are around 20%) and
the requirement of expensive equipment and well-trained
researchers which limits the eﬃciency of this approach. To
overcome this disadvantages Bush and collaborators [97]
developed a femoral artery version of this model that uses
the same thrombogenicity coils but consists of Doppler ﬂow
probes placed proximal to the site of thrombosis and thus is
also appropriate to use in rabbits.
Another model of coronary thrombosis in open-chest
dogs is based on the local delivery of thrombin in the
LADcoronary artery. This approach inducesﬁbrin-rich clots
amenable to lyse upon thrombolytic administration [98].
5.InsightsfromVonWillebrand Disease in
LargeAnimalModels
Von Willebrand disease (VWd) is a genetic bleeding disorder
that arises from the abnormalities in VW factor (VWF).
It is the most common inherited bleeding disorder in
humans, and over the past years several animal species
have also been described as suﬀering from this disease
whether through spontaneous mutation (pigs and dogs) or
through a genetically engineered mutation (mice) [6]. All
these diﬀerent animal models have been extremely useful
in exploring the characteristics of VWd and in testing new
treatments. Indeed, the interaction of platelets with VWF is
crucial in the initiation and development of any thrombotic
process since enables platelets, via its surface glycoprotein
receptors, to adhere to exposed subendothelium and to
respond to blood shear stress [111–113]. In fact, we and
Fuster et al. [36, 109]w e r ea m o n gt h eﬁ r s tt os h o was t r i k i n g
diﬀerence in the atherosclerotic lesions in the aorta between
normal pigs and VWd pigs, both in spontaneous and in diet-
induced atherosclerosis, demonstrating protection against
atherosclerosis in VWd pigs. The pig is a good model for
studying VWd since VWF localization in endothelial cells
and platelets mimics that of humans as do the clotting and
platelet characteristics. Additionally, in normal pigs the level
of VWF is close to the human level [6]. Canine VWd has also
demonstrated to be similar to humans. Over the years, many
dogbreedshavebeenidentiﬁedassuﬀeringfromthisdisease,
making VWd the most common inherited bleeding disorder
in dogs. However, underthe term“canine VWd”, there seems
to be a very heterogeneous group of bleeding disorders
with diﬀerent subtypes and mode of inheritance [114].
Actually, canine VWd can vary in genetic transmission,
clinical severity and diagnostic laboratory ﬁndings. Thus, in
contrasttopigs,VWddogshavenotbeenusedextensivelyfor
research purposes [115]. Finally, it deserves to be mentioned
thatVWdhasalsobeenreported inotheranimal speciessuch
as murine [116, 117],rabbits[118], and cats [119]. However,
caution must be taken in extrapolating such results to the
human clinical conditions.
6.Animal ModelsofPlaqueRupture
By its very nature, rupture of an atherosclerotic plaque is
diﬃcult to study in humans. Moreover, since rupture of
an atherosclerotic plaque occurs in a stochastic fashion, it
is also diﬃcult to identify triggering factors and equally
hard to investigate treatments addressed towards plaque
stabilization. Thus, the appropriate animal model, not only
should help to better understand the mechanisms behind
plaque rupture but also test treatments to prevent it from
happening. Despite the development of porcine models of
advanced human-like coronary atherosclerosis, no suitable
large animal model of high-risk (vulnerable) plaque exists.
In fact, spontaneous hemorrhage and rupture is considered
an extremely rare event in large animal models and has
only been found in the coronary arteries of pigs with
inherited hyper-low-density lipoprotein cholesterolemia or
in cholesterol-fed pigs with streptozotocin-induced diabetes
[120, 121]. Lack of such a model has hampered studies
designed to validate imaging technologies and to scrutinize
the eﬀects of therapeutic interventions in atherosclerotic
arteries.
In the recent years, many rodent studies have been
published with “vulnerable-likefeatures”. Some authorshave
described the presence of blood-ﬁlled channels within the
a d v a n c e dc o r o n a r yl e s i o n sa sw e l la sp l a q u er u p t u r e sa n d
thrombi in the aortic origin of old apolipoprotein E−/− (Apo
E−/−)m i c e[ 122, 123], whereas other studies have reported
the presence of luminal thrombi in ruptured plaques of6 Journal of Biomedicine and Biotechnology
Table 2: Diﬀerent animal models in order to evaluate thrombus formation.
Reference Method applied in order to induce plaque rupture and/or thrombus
formation Animal model
Reddick et al. [99] Forceps squeezing of the aorta Apo E−/− mice
Gertz et al. [100]
Rekhter et al. [101]
Combination of double ballon injury and hypercholesterolemia and further
angioplasty-induced plaque rupture Rabbits
Eitzman et al. [102] Photochemical reaction to previously formed atherosclerotic plaques Apo E−/− mice
Constantinides et al. [103]
Abela et al. [104]
Nakamura et al. [105]
Intraperitoneal injection of Russell’s viper venom∗ followed by i.v. injection
of histamine(vasopressor),serotonin or angiotensin II Hypercholesterolemic rabbits
Rekhter et al. [106] Intracerebroventricular injection of corticotrophin-releasing factors (“stress
hormone”) Apo E−/− mice
Heras et al. [107] Carotid angioplasty Pig
Badimon et al. [52, 108]
Lassila et al. [65]
Thrombogenic eﬀect of shear stress and atherosclerotic vessel components on
the extracorporeal perfusion system Pig
Badimon et al. [36]
Fuster et al. [109, 110] Von Willebrand factor deﬁciency Pigs with von Willebrand
disease
∗Procoagulant and endothelial toxin.
spontaneously dead Apo E−/− mice [124]. Yet, the relevance
of these mice models of plaque rupture on the ﬁnal events
precipitated by plaque disruption of human atherosclerotic
lesions is controversial, especially in animals surprisingly
resistant to formation of thrombi at sites of atherosclerosis
[125].
On the other hand, other investigators have evaluated
the harmful eﬀect of combining several risk factors. As such,
it has been reported that either in double knockout mice
with homozygous null mutations in the Apo E and the
high-density lipoprotein (HDL) receptor, scavenger receptor
class B, or combination of hypertension and dislipemia
(hypertensive rats transgenic from human cholesteryl ester
transfer protein) increase plaque vulnerability and thrombi
formation.
Rabbits have been used as a model of plaque instability
and rupture [101, 104], besides their extended use in animal
models of atherogenesis [100, 126], myocardial infarction
[127], and to evaluate the eﬃcacy of new antithrombotic
and anti-atherosclerotic drugs [128]. Moreover, transgenic
rabbits have also been developed to obtain models of hered-
itary hyperlipidemia (WHHL-rabbit). Rabbits are easy to
handleandcost-eﬀectiveandtherearethreebreedsofrabbits
that have been commonly used in biomedical research: New
Zealand White, Dutch Belted and Flemish Giant. Although
rabbits do not develop spontaneous atherosclerosis, as they
are vegetarian, we and others have robustly demonstrated
that they can rapidly develop foam-cell-rich (fatty steaks)
plaques after the administration of a rich atherosclerotic diet
(0.5%–4%cholesterolcontent)during8–16weeks[129].Yet,
rabbit atherosclerotic lesions diﬀer from human atheroma
since their lipid and macrophage content is much higher
as it is their hypercholesterolemic index [130]. Conversely,
intermittent cycles of fat feeding with periods of normal
diet has shown to induce plaques at more advanced stages
that resemble human atheroma [131]. In addition, we have
shown that combining cholesterol-rich feeding with arterial
wall injury (e.g., balloon injury) induces advanced lesions in
shorter periods [100, 104, 132–135].
The addition of pharmacological triggering at the end
of the atherogenic diet has provided the ﬁrst evidence of
thrombosis associated with plaquesin this experimental ani-
mal model, the Constantinides New Zealand white (CNZW)
rabbit model, with similarities to thrombosis seen in human
coronary arteries [103]. Furthermore, these observations
have been supported by in vivo magnetic resonance imaging
[136]andmolecular-targetedimaging, usingaﬁbrin binding
peptide conjugated to gadolinium, which have clearly shown
thrombus superimposition to the atherosclerotic lesion
[137]. In counterpart, CNZW rabbit model similarity to
humanatherothrombosishasbeenquestionedeitherbecause
rabbits’ atherosclerotic lesion composition (i.e., foam-cell-
rich rather than complicated plaques) and concerns about
the triggering method used to induce plaque disruption and
thrombosis [101, 130, 138].
Other more simplistic approaches (e.g., direct mechan-
ical injury of the vessel of interest) with a lower impact
for clinical translation have been also developed in diﬀerent
animal models as described in Table 2
7.Animal ModelsofVenousThrombosis
Thrombogenesis in veins is mainly attributed to some com-
bination of hypercoagulability, stasis, and vascular injury.
All these triggering factors induce tissue thromboplastin
(tissue factor) release totheﬂowing bloodforming thrombin
and ﬁbrin that trap red blood cells. Thus, in contrast to
arterial thrombotic lesions (platelet-rich thrombus, “white
thrombus”), venous thrombosis is predominantly “red” and
ﬁbrin rich.
Animal models for venous thrombosis appear to be
particularly useful forstudying thepathophysiologyofblood
coagulationin vivo andthepathogenesisofvenousthrombo-
sis. For instance, this model has helped to deﬁne the role of
activated protein C, the interplay between inﬂammatory and
procoagulant mediators, and the regulatory role of PAI-1 in
thrombolysis besides therapeutic approaches [139]. In fact,Journal of Biomedicine and Biotechnology 7
D¨ orﬄer-Melly et al. [140]a n dL e v i[ 139]h a v ep r e v i o u s l y
published interesting literature of small and large animal
models of venous thrombosis, pointing out their advantages,
usefulness, and limitations.
8.Conclusionsand FuturePerspectives
Clinical observations provide the substrate to build up
pathophysiological hypotheses, but for obvious ethical rea-
sons our ability to test these hypotheses in humans is very
limited. Cell biology-related studies have helped to answer
mechanistic questions, but lack complexity of a real disease
thus limiting the scope of testable hypotheses. On the other
hand, studies using rodent or large animal models have
proved to be essential for proof of concept since they yield
in vivo approaches to conﬁrm critical hypotheses previously
evaluated in relevant in vitro models. Experience over many
decades has established that a single, naturally available
model of human vascular disease does not exist. The advent
of genetic engineering and the availability of transgenic
and knockout animals have allowed pinpointing the relative
functional importance of single changes in speciﬁc gene
products. These approaches have permitted uncovering
speciﬁc gene functions and have facilitated the formulation
of new strategies for cardiovascular protection and the
prevention and treatment of atherothrombosis. However,
their utility as models of human disease and to prove the
validity of products for human pharmacological use has not
beendemonstrated.Animal modelshavehelpedtoaccelerate
the rate of new target identiﬁcation and validation leading
to improved therapeutics for the atherothrombotic disease.
However, while small animal models provide experimental
convenience and easiness to manipulate, more clinically
relevant models are necessary to study the mechanisms
involved in human atherothrombogenesis. Large animal
models, although associated to a higher cost and handling-
related diﬃculties, have shown an atherothrombotic pattern
more comparable to that of humans. To date, considering
all models, the porcine model is one of the most useful
currently available atherothrombotic models. Indeed, pig
animal models have shown to address speciﬁc questions
related to blood and atherosclerotic vessel mechanisms
involved in thrombus formation that have been eventually
translated to clinical situations. Despite all this, eﬀorts for
developing the “ideal” animal model for atherothrombotic
evaluation must continue as well as the development of
state-of-the-art technology in order to achieve improved
therapeutic strategies capable of further reducing the global
burden of vascular atherothrombotic disease in humans.
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